As of 2024-12-13, the EV/EBITDA ratio of Replicel Life Sciences Inc (RP.V) is
1.61.
EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RP.V's latest enterprise value
is 0.68 mil CAD. RP.V's TTM EBITDA according to its financial statements is
0.42 mil CAD. Dividing these 2
quantities gives us the above RP.V EV/EBITDA ratio.
|
Range |
Selected |
| Trailing P/E multiples |
12.3x - 14.2x |
12.6x |
| Forward P/E multiples |
13.2x - 14.7x |
14.7x |
| Fair Price |
0.08 - 0.09 |
0.09 |
| Upside |
690.1% - 846.6% |
778.7% |